Accordingly, reprogramming the glycolytic properties of CAFs by inhibiting the GLUT1 glucose transporter led to decreased Cxcl16 expression in the glyCAF and increased infiltration of cytotoxic CD8+ T cells into the tumor, independent of cancer cell-intrinsic metabolism and other immune cells in the TME. The gene discussed is CXCL16; the disease is neoplasm.